Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBUL0 Apremilast in Epidermolysis Bullosa Simplex Generalized Severe
2023-508794-83-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apremilast in epidermolysis bullosa simplex (EBS), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Primary efficacy of apremilast in severe generalized EBS. Planned start Jun 2024; status: authorised.
02
Drugs
apremilast
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on 2023-508794-83-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508794-83-00.